News|Articles|October 4, 2014
The Toxicity Profile of Concurrent Nivolumab and Ipilimumab
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.
- Additive toxicity was found between these agents.
- The grade 3/4 adverse event rate was greater than 50%.
- Most adverse events were reversible with immunosuppressants.
<<<
Related Content
Advertisement
